Biovie Inc (BIVI)

$0.46

+0.03

(+6.33%)

Market is closed - opens 7 PM, 15 Jul 2024

Performance

  • $0.44
    $0.47
    $0.46
    downward going graph

    3.76%

    Downside

    Day's Volatility :4.8%

    Upside

    1.08%

    downward going graph
  • $0.40
    $5.82
    $0.46
    downward going graph

    13.04%

    Downside

    52 Weeks Volatility :93.13%

    Upside

    92.1%

    downward going graph

Returns

PeriodBiovie Inc
3 Months
-5.87%
6 Months
-63.19%
1 Year
-90.82%
3 Years
-96.95%

Highlights

Market Capitalization
26.7M
Book Value
$0.31
Earnings Per Share (EPS)
-0.93
Wall Street Target Price
3.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-62.32%
Return On Equity TTM
-178.58%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-38.1M
Diluted Eps TTM
-0.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.18
EPS Estimate Next Year
-0.58
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Biovie Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
7
Hold
3
3
1
Sell
3
3
00

Analyst Forecast

What analysts predicted

Upside of 552.17%

Current $0.46
Target $3.00

Technicals Summary

Sell

Neutral

Buy

Biovie Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biovie Inc
Biovie Inc
0.8%
-63.19%
-90.82%
-96.95%
-95.36%
Moderna, Inc.
Moderna, Inc.
-13.26%
18.89%
0.09%
-50.76%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.13%
17.36%
53.1%
89.32%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
77.44%
226.85%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.67%
11.71%
38.56%
146.98%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biovie Inc
Biovie Inc
NA
NA
NA
-1.18
-1.79
-0.62
NA
0.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biovie Inc
Biovie Inc
Sell
$26.7M
-95.36%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • Altium Capital Management, LP

    4.94%
  • Sabby Management LLC

    1.13%
  • Vanguard Group Inc

    1.06%
  • CVI Holdings LLC

    0.98%
  • Renaissance Technologies Corp

    0.57%
  • BlackRock Inc

    0.54%

Company Information

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo

Organization
Biovie Inc
Employees
18
CEO
Mr. Cuong Viet Do M.B.A.
Industry
Biotechnology

FAQs